… 1-year real-life risk of major clinical events with dabigatran or rivaroxaban versus … real-life
effect of dabigatran and rivaroxaban compared with VKAs, as used in the general population. …

… for the comparison between dabigatran and warfarin (Figure 3). The risk of stroke was lower
with dabigatran than warfarin, and this superiority of dabigatran was more pronounced in …

… in real-world settings. The objective of this study is to implement this novel design to evaluate
safety and effectiveness of dabigatran … of dabigatran initiators were switched from warfarin. …

… populations, in the real world. Thus, the importance of observational studies in depicting ‘the
real world’ is … at 27,538 dabigatran-rivaroxaban patient pairs. This study which compared …

… and safety. While larger than most severe obesity studies to date, our study had a smaller
cohort compared to most real-world dabigatran studies in the general AF population and …

… the clinical effectiveness and safety of dabigatran compared with warfarin … safety of dabigatran
110 mg or 150 mg twice daily (BID) were also shown in Japanese and Asian populations …

… persistence rates of 11,350 dabigatran users were 24.5… dabigatran is a relatively new drug
in China. Compared with other reported data, patients of this study have (1) lower dabigatran …

… We also recorded indications for dabigatran use, the daily dabigatran dosage, and laboratory
data both before and after idarucizumab infusion, including creatinine clearance, activated …

… Our data highlight that across a broad patient population, the real-world safety and effectiveness
of dabigatran compared to VKAs do not differ from those of the randomized clinical trial …

… how well real-world patients with a broad spectrum of creatinine clearance would achieve
target plasma dabigatran trough concentrations associated with efficacy and safety. However, …